Vitamin D deficiency is the state of having inadequate amounts of vitamin D in your body, which may cause health-related ...

BioMarin Pharmaceutical Inc. and Inozyme Pharma, Inc. announced that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transaction for a total ...

BioMarin Pharmaceutical has agreed to acquire Inozyme Pharma for $4.00 per share in a $270m all-cash transaction. This will ...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Inozyme Pharma, Inc. (Nasdaq: INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an ...

BioMarin has entered into a definitive agreement to acquire Inozyme Pharma Inc. for a total consideration of approximately ...

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 DeficiencyFirst Pivotal Data Readout in Children ...

Medically reviewed by Femi Aremu, PharmD Vitamin D3 (cholecalciferol) is a form of vitamin D naturally found in some foods ...

The major therapeutic uses of vitamin D include treatment of nutritional or metabolic rickets; osteomalacia, particularly in the setting of chronic renal failure; hypoparathyroidism; and osteoporosis.